Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Liang Kong Reports | China HealthCare & Pricing System Reform 2008

China HealthCare & Pricing System Reform 2008

China represents one of the fastest growing pharmaceutical markets in the world and is the most lucrative market in Asia. Since 1978, the annual growth rate for China pharmaceutical market has kept for more than 15% every year. So no one can neglect the huge potential of China with its pharmaceutical market that is expanding greatly day by day.

China pharmaceutical pricing and reimbursement is a complex and ever-changing area. In a rapidly evolving market it is essential that executives are briefed on the regulatory systems that determine the way in which your company operates and sells its products. The pricing and reimbursement of prescription pharmaceuticals is a critically important issue for both the research-based and generic drug industry everywhere in the world where drug prices are not left to the forces of the free market and competition, definitely included China.

The Healthcare & pricing reform in China - Understanding the pharmaceutical market in the healthcare system is a straightforward guide to the pricing and reimbursement mechanisms in China market, in particular recent reforms since 2007 and the current proposed healthcare reform in the end of 2008.

This report is aimed to add to the understanding of some of the mechanisms that have been adopted in China markets, and to identify the major topics of interest and concern to health insurers, governments and the industry. The following are explained clearly in the report: how the healthcare system developed, the current state of healthcare in the country and the processes for negotiating drug reimbursement. The flaws in the system and look at government attempts and industry pressure for reform were also detailed.

The 162 page report also clearly explains the structure of the healthcare system and the regulations and arrangements in place that provide the framework for setting medicine prices and gaining reimbursement in China.

Reasons to read this report:

Stay up-to-date with the latest trends in China pharmaceutical pricing & reimbursement

Save time by concisely explaining the key elements of pricing and reimbursement regulation in China

Understand the principles of China future healthcare reform & pricing reform

Gain insight into latest policies and the political environment affecting the reimbursement of medicines

Increase your knowledge of the ways in which governments influence and control the pharmaceutical industry

Forecast how governments will implement drug spending cost containment measures.

ABOUT THE AUTHOR

Liang Kong enrolled in the prestigious China Pharmaceutical University in 1997, where he majored in international pharmaceutical trade. He subsequently continued graduate study of pharmaceutical administration, and was appointed a research executive from 2001 to 2003 at China‘s Nanjiing Yaxing Marketing Research Company, which specializes in pharmaceuticals. Subsequently, he was appointed to be a sales manager of a pharmaceutical company from 2003 to 2004. From 2004 to 2006, he was assigned as a project manager in APEX, an Asia CRO, for clinical trials in China or the other Asian countries. Mr. Kong has a deep understanding of China pharmaceutical market and regulations, and has supplied service for many China and international pharmaceutical companies. He has a wide connection with China pharmaceutical industry. He has provided a lot of presentations on China market and regulation in all kinds of conference and published a lot of reports regarding China pharmaceutical industry. Mr. Kong also shows great interest with the other Asia countries pharmaceutical market and regulation and he has made some research on them through his effort. Mr. Kong has published articles in the journals China Pharmaceuticals and China Pharmacy, as well as acting as correspondent to international pharmaceutical publications, and also consultant to some international pharmaceutical companies.

November 2008 Pages: 156 Format PDF
Price: $1,200.00 / €794.76

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions